title: Use of hormone therapy for menopausal symptoms and quality of life in breast cancer survivors. Safe and ethical?
abstract: Breast cancer is the most prevalent cancer in women and presently, the breast cancer survivors are an important group of women that faced the several consequences of estrogen deficiency, which is especially common in women after chemotherapy. The most bothersome is the vasomotor symptoms, which are effectively relieved by hormonal therapy (HT). Also, the increased risk of osteoporosis and coronary artery disease is major problem to be resolved in pos of maintaining a good quality of life. Fearing cancer recurrence, most physicians do not offer HT to women with a history of breast cancer. Over this issue reviews the available evidence of the use of HT and tibolone in women treated for breast cancer.
authors.affiliation: a Department of Obstetrics & Gynecology and Reproductive Biology , Faculty of Medicine, Universidad de los Andes , Santiago , Chile and.
authors.forename: María Fernanda
authors.initials: MF
authors.lastname: Garrido Oyarzún
authors.affiliation: b Clinic Institute of Gynecology, Obstetrics and Neonatology, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona , Barcelona , Spain.
authors.forename: Camil
authors.initials: C
authors.lastname: Castelo-Branco
mesh_terms: D001943:Breast Neoplasms; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000941:ethics / Q000592:standards*; D006801:Humans; D008593:Menopause; D016649:Primary Ovarian Insufficiency / Q000188:drug therapy*; D011788:Quality of Life; D017741:Survivors
keywords: Breast cancer; cancer survivors; estrogen–progestin therapy; hormone therapy; menopausal symptoms; tibolone